Supernus Pharmaceuticals, Inc. (SUPN)
Market Cap | 1.98B |
Revenue (ttm) | 667.24M |
Net Income (ttm) | 60.71M |
Shares Out | 54.38M |
EPS (ttm) | 1.04 |
PE Ratio | 34.99 |
Forward PE | 20.16 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 251,004 |
Open | 36.20 |
Previous Close | 36.40 |
Day's Range | 34.37 - 36.59 |
52-Week Range | 24.95 - 42.09 |
Beta | 1.01 |
Analysts | Buy |
Price Target | 43.61 (+19.84%) |
Earnings Date | May 8, 2023 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The ... [Read more]
Full Company ProfileFinancial Performance
In 2022, SUPN's revenue was $667.24 million, an increase of 15.09% compared to the previous year's $579.78 million. Earnings were $60.71 million, an increase of 13.64%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is $43.61, which is an increase of 19.84% from the latest price.
News

Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

Supernus to Present at the Cowen 43rd Annual Health Care Conference
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
1 Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Enters Into $150 Million Credit Facility
ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN). Such investors a...

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Provides Regulatory Update on SPN-830
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra...

Supernus to Present at the 2022 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Best Momentum Stocks to Buy for August 8th
CLH, NETI and SUPN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2022.

Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Announces Second Quarter 2022 Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus to Participate in the Jefferies Healthcare Conference
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Announces First Quarter 2022 Financial Results
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients
The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult pa...

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md. , May 2, 2022 /PRNewswire/ -- Supernus Pharmaceuticals, Inc. (N...

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...